Elicio Therapeutics Inc. (ELTX) Stock Forecast & Price Target
Elicio Therapeutics Inc. · NASDAQ
$2.93-0.07 (-2.33%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 5 firms covering Elicio Therapeutics Inc, 4 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $12.00 to $27.00 (about 2.3x), a sign of real disagreement on valuation. The average target of $19.75 sits 574% above the current $2.93. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 3 to 4 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.47 next quarter toward $-2.43 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 ratings
Moderate Buy
Strong Buy00%
Buy480%
Hold120%
Sell00%
Strong Sell00%
Based on 5 analysts giving stock ratings to Elicio Therapeutics Inc.
As of Jul, 4 of 5 firms rate ELTX a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ELTX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.47
Range $-0.60 – $-0.39 · 4 analysts · -21% YoY
Next period, 4 analysts expect Elicio Therapeutics Inc. to earn $-0.47 a share (range $-0.60 – $-0.39), versus $-0.60 a year earlier. Full-year consensus is $-2.07, growing to $-2.43 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 4 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Elicio Therapeutics Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ELTX.
#1
Mayank Mamtani
B. Riley Securities · Rank #9
Buy
$27.00+821.5% to target
Overall win rate
53%
+ Follow
#2
RB
Robert Burns
HC Wainwright & Co. · Rank #195
Buy
$23.00+685.0% to target
Overall win rate
38%
+ Follow
#3
Aydin Huseynov
Ladenburg Thalmann · Rank #361
Buy
$20.00+582.6% to target
Overall win rate
34%
+ Follow
#4
MK
Michael King
Rodman & Renshaw
Buy
$17.00+480.2% to target
Coverage
—
+ Follow
#5
KD
Kevin DeGeeter
Ladenburg Thalmann
Buy
$12.00+309.6% to target
Coverage
—
+ Follow
ELTX stock forecast FAQ
What is ELTX's average 12-month price target?+
The 4 analysts with a live target average $19.75 for Elicio Therapeutics Inc. over the next 12 months, ranging from a $27.00 high to a $12.00 low.
Is ELTX stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 5 analyst ratings, 4 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ELTX?+
The Street-high target is $27.00 (B. Riley Securities), and the Street-low is $12.00 (Ladenburg Thalmann). The average of all 4 active targets is $19.75.
How many Wall Street analysts cover ELTX?+
5 analysts have an active rating on Elicio Therapeutics Inc., and 4 firms carry a live 12-month price target.
Who is the most accurate analyst covering ELTX?+
Among analysts who currently cover ELTX, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #9). Their current call is Buy with a $27.00 target.
What is Elicio Therapeutics Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.47 per share (range $-0.60 – $-0.39) across 4 analysts. Full-year EPS is projected at $-2.07, rising to $-2.43 the following year.
How much revenue is Elicio Therapeutics Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading ELTX lately?+
As of Jul, 4 of 5 firms rate ELTX a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ELTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
